Isomorphic Labs Secures $5 Billion in Series C Funding for AI-Powered Drug Development
On November 17, 2026, Isomorphic Labs, a company specializing in artificial intelligence for drug design and development, announced that it has successfully closed a Series C funding round amounting to $5 billion. This funding was co-led by prominent firms Greenoaks and Sequoia Capital, alongside significant participation from Andreessen Horowitz (a16z) and other new investors. Alphabet, a key player among existing investors, also continued to bolster its investment. The list of previous investors includes Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign Fund for AI, indicating broad support from the investment community.
Isomorphic Labs is pioneering the use of its proprietary drug design engine, IsoDDE, which integrates various AI models functioning across multiple therapeutic areas and drug modalities. IsoDDE allows the company to explore extensive chemical spaces, enabling its world-class team to design, refine, and produce high-quality engineered molecules with optimal drug-like properties. It is the precision and scope of IsoDDE’s simulation models that lead to process predictions of experimental accuracy, offering crucial functionalities that propel innovative drug discovery.
Significantly, these AI-driven tools are designed to navigate complex biological systems, continually translating their capabilities into advancements across the organization’s extensive therapeutic candidate portfolio, tackling some of the most challenging problems in the pharmaceutical industry. The results thus far have indicated positive outcomes in preclinical trials, particularly in oncology and immunology programs, as well as collaborations with partners setting the stage for clinical trials.
The influx of capital is set to accelerate the scientific breakthroughs and advancements in proprietary AI being developed by Isomorphic Labs. With the aim of not only developing IsoDDE further but also delving deeper into new biological pathways through advanced modeling techniques, Isomorphic plans to establish a partnership ecosystem to enhance understanding of the mechanistic biology of diseases. Concurrently, the company is laying down the global infrastructure required for the future of AI-driven biodesign, ensuring scalability and efficiency as they progress their drug candidates toward clinical trials.
Demis Hassabis, the founder and CEO of Isomorphic Labs, commented on the funding, stating, "When we founded Isomorphic, we were convinced that biology could be understood and modeled at the most fundamental molecular level and radically accelerated through AI. Our drug design engine generates molecules with unprecedented accuracy and speed. This round of funding enables us to quicken our advancements in developing fundamental biological models, deepen our understanding of systemic diseases, and move our first therapeutic programs toward clinical trials to make a real impact for patients."
Max Jaderberg, president of the company, added that they are achieving reproducible scientific advancements weekly through their models, which translate directly into improved molecular profiles that can lead to new drug discoveries, addressing some of the most difficult challenges in drug discovery. He emphasized the importance of interdisciplinary collaboration within their teams, comprising world-renowned machine learning researchers and high-caliber drug discovery specialists, who together solve biological problems that have hindered traditional research for decades. Isomorphic is thus poised to translate their findings into potentially revolutionary medicines, aided by the infrastructure they are building to support the future of biodesign.
Neil Mehta, founder and managing partner at Greenoaks, acknowledged the monumental challenge of discovering and developing new drugs, expressing confidence that Isomorphic is transforming this space by building deep learning systems capable of accurately predicting complex biological behaviors and systematically mapping paths toward new medications. He underlined Greenoaks' pride in partnering with Isomorphic on this crucial mission.
Konstantine Buhler, a partner at Sequoia Capital, remarked on Isomorphic Labs as constructing foundational technology for the future of medicine, praising the team for translating advanced AI into a growing portfolio of drug candidates. He emphasized the vital importance of using AI to improve human health, reaffirming Sequoia’s commitment to progressing scientific discovery in medicine through this financing cycle.
Founded in 2021, Isomorphic Labs seeks to revolutionize drug discovery by leveraging the power of artificial intelligence, heralding a new era of biomedical breakthroughs. With a dedicated team under the leadership of CEO Sir Demis Hassabis and President Max Jaderberg, Isomorphic Labs boasts a cutting-edge AI drug design engine, continually innovating in model architecture and capabilities to enhance drug discovery processes. Headquartered in London, with additional offices in Cambridge, Massachusetts, and Lausanne, Switzerland, the company is ambitiously advancing a comprehensive drug design portfolio through both partnership-led initiatives and wholly-owned internal programs.